Duchenne muscular dystrophy is a genetic disease that causes progressive muscle weakness, usually diagnosed in boys around age 3-5. About 1 in 3,500 boys are born with it. Corticosteroids remain the standard treatment to slow decline, while newer therapies target specific genetic mutations or aim to increase functional dystrophin protein.
What's actually going on in research
Trials are testing gene therapies that deliver working copies of the dystrophin gene, exon-skipping drugs that restore partial dystrophin production for specific mutations, and drugs that increase utrophin or reduce inflammation. Several gene therapies received accelerated FDA approval between 2020-2023, though long-term benefit is still being studied. Researchers are also testing heart and breathing treatments, since these complications drive mortality.
Gene therapy
Several gene therapies now deliver micro-dystrophin genes using AAV vectors. Early results show some boys produce measurable dystrophin and maintain walking ability longer than expected.
Exon skipping
Drugs like eteplirsen and golodirsen work for boys with specific deletions, skipping over damaged sections of the gene to produce shorter but functional dystrophin. Additional exon-skipping drugs are in trials to cover more mutation types.
Heart protection
Heart failure is a leading cause of death in Duchenne. Trials are testing whether starting heart medications earlier, before symptoms appear, can delay cardiac decline.
What to know before you search
Eligibility depends on age, walking ability, specific genetic mutation, prior steroid use, and heart or lung function. Gene therapy trials often require boys under 7-10 who are still walking.
What types of trials are currently open
- Gene therapy trials — Testing one-time infusions that deliver working dystrophin genes. Most require boys to be ambulatory and under age 7-10.
- Exon-skipping trials — Testing weekly or monthly infusions of drugs that restore partial dystrophin for specific genetic mutations, usually exon 45, 51, or 53 deletions.
- Anti-inflammatory trials — Testing drugs that reduce muscle inflammation and fibrosis, which drive progressive weakness.
- Cardiac trials — Testing heart medications started early to delay cardiomyopathy, the heart muscle weakness that develops in most people with Duchenne.
- Observational studies — Following boys with Duchenne to measure disease progression, functional outcomes, and response to treatments over time.
Recently added Duchenne Muscular Dystrophy trials
Take a nutritional supplement designed for Duchenne muscular dystrophy
This pilot study will investigate the potential efficacy of VM100, a nutritional supplement specifically formulated for patients with DMD, on quality of life and physical symptoms. Twenty patients (aged 8 an over) will be enrolled to undergo a 10-week placebo-controlled intervention with VM100. Outcomes will include validated questionnaires and qualitative interview to assess impact on mental, cognitive and mood related measures, as well as endurance and fatigue).
Share heart imaging scans to help predict outcomes in Duchenne muscular dystrophy
Dystrophin associated heart dysfunction is a leading cause of death in patients with Duchenne and Becker Muscular dystrophy (DMD/BMD) and Duchenne and Becker muscular dystrophy carriers (MDC); however, the evolution of heart dysfunction is not well-understood. The central objectives of this proposal are to elucidate this evolution of heart dysfunction and identify measures from cardiac MRI images that can predict death or significant heart disease in patients with DMD/BMD/MDC. This study will create a large clinical and cardiac MRI registry of dystrophin associated heart dysfunction, will utilize advanced image analysis techniques, including deep learning neural networks, to comprehensively evaluate every patient, and will create a risk toolkit accessible to clinicians around the world; this proposal has the potential to improve the quality of life in patients with dystrophin associated heart dysfunction by allowing for earlier and more intensive therapy in patients with severe disease and by identifying surrogate outcome measures for use in therapeutic trials.
Find Duchenne Muscular Dystrophy trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.